GM-2505 is a psychedelic and experimental antidepressant that acts as a 5-HT2A and 5-HT2C receptor agonist and serotonin releasing agent.[1][2] Compared to other 5-HT2A receptor agonists, it has a shorter duration of action.[2][3] As of March 2024, it is in phase 2 clinical trials for the treatment of major depressive disorder.[1]
 | |
| Clinical data | |
|---|---|
| Drug class | Psychedelic; Serotonin 5-HT2A and 5-HT2C receptor agonist; Serotonin releasing agent |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C12H19N5 |
| Molar mass | 233.319 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
References
edit- ^ a b "GM 2505". AdisInsight. 22 March 2024. Retrieved 30 August 2024.
- ^ a b Conference-poster: Hughes, Zoe; Klein, Adam; Dvorak, Dino; Austin, Eric; Kiss, Laszlo; Marek, Gerard; Sporn, Jonathan; Kruegel, Andrew (2023). "22. GM-2505 has Rapid Onset Antidepressant Activity and Causes Dose-Dependent Changes in qEEG With Increasing 5-HT2A Receptor Occupancy". Biological Psychiatry. 93 (9): S102–S103. doi:10.1016/j.biopsych.2023.02.262.
- ^ Beaney, Abigail (6 December 2023). "Gilgamesh to initiate Phase IIa trial of fast-acting psychedelic drug". Clinical Trials Arena. Retrieved 7 December 2023.